白血球接着不全管理の世界市場レポート 2024年

白血球接着不全管理の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.7%の年間複合成長率（CAGR）で104億6,000万米ドルに成長すると予想されます。白血球接着不全症の管理の予測期間における予想される成長は、精密医療アプローチの採用、新しい治療法の出現、遺伝子検査へのアクセスのしやすさの向上、患者中心の医薬品開発への移行、と免疫調節の進歩に起因すると考えられます。治療法。予測期間に予想される主要動向には、幹細胞移植技術の革新、支持療法の統合、遠隔診療のための遠隔医療の使用、調査ネットワーク内での協力、診断と治療戦略を強化するためのバイオマーカー技術の組み込みなどが含まれます。

原発性免疫不全症（PID）の発生率の上昇により、白血球接着不全管理市場の拡大が促進されると予想されます。 PIDには、免疫系の機能を損なうさまざまな遺伝性疾患が含まれており、免疫応答の欠陥により個人が感染症や病気に対してより脆弱になります。白血球接着不全の管理は、原発性免疫不全症患者にとって大きな利益となり、免疫系疾患の理解を深め、これらの症状に対する改良された診断技術や治療法の開発を促進する可能性があります。たとえば、2023年の世界原発免疫不全症（WPI）啓発週間中に平和病院が収集した統計によると、世界中で推定600万人がPIに罹患しており、症例の70%～90%が未診断のままであることが示されています。したがって、原発性免疫不全症の有病率の上昇は、白血球接着不全管理市場の成長を促進すると予想されます。

脊髄損傷の有病率の増加は、白血球接着不全管理市場の成長を促進すると予想されます。脊髄損傷は、脊髄または関連する神経の一部の損傷に起因し、多くの場合、多汗症などの症状を含む自律神経機能障害などの合併症を引き起こします。この問題は、損傷部位のすぐ下に位置する脊髄部分の交感神経活動の亢進に関連しています。 2022年 3月に国立脊髄損傷統計センター（NSCISC）が示したように、米国における外傷性脊髄損傷（SCI）の推定年間発生率は100万人あたり約54件であり、これは約1万8,000件の新たな脊髄損傷に相当します。毎年。さらに、米国におけるSCIを抱えて生きる人の推定数は25万3,000人から37万8,000人の範囲であり、合計で約29万9,000人になります。したがって、脊髄損傷の有病率の増加は、白血球接着不全管理市場の成長に貢献します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の白血球接着不全管理市場の促進要因の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の白血球接着不全管理の市場規模実績と成長、2018～2023年
• 世界の白血球接着不全管理市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の白血球接着不全管理市場、治療別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 造血幹細胞移植
• 組換えヒトインターフェロンガンマ治療
• 予防的免疫グロブリン療法
• 抗菌療法
• 予防療法
• フコース補給
• モノクローナル抗体
• 凝固因子
• 世界の白血球接着不全管理市場、診断別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 血液検査
• 遺伝子検査
• 生検
• その他
• 世界の白血球接着不全管理市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• 専門クリニック
• その他

第7章 地域と国の分析

• 世界の白血球接着不全管理市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の白血球接着不全管理市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 白血球接着不全管理市場の競合情勢
• 白血球接着不全管理市場企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • GlaxoSmithKline Plc
  • Gilead Sciences Inc
  • Teva Pharmaceuticals Industries Limited

第31章 その他の大手と革新的な企業

• CSL Behring LLC
• Vertex Pharmaceuticals Inc.
• Grifols International SA
• Aurobindo Pharma Ltd.
• BioMarin Pharmaceutical Inc.
• Cadila Healthcare Ltd.
• Ipca Laboratories Ltd
• Sana Biotechnology Inc.
• Rocket Pharmaceuticals Inc.
• PT Sanbe Farma
• Magenta Therapeutics Inc
• Avalo Therapeutics Inc.
• Aspen Neuroscience Inc.
• Sandoz International GmbH
• Orpha Labs Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Leukocyte Adhesion Deficiency (LAD) is a rare genetic disorder that impacts the immune system's ability to combat infections, specifically by affecting the adhesion of white blood cells, particularly neutrophils. These cells are crucial for defending the body against bacteria and fungi. Managing leukocyte adhesion deficiency requires a comprehensive approach, focusing on preventing and treating infections while addressing the underlying immune system dysfunction.

The primary treatments for managing leukocyte adhesion deficiency include hematopoietic stem cell transplantation, recombinant human interferon-gamma treatment, prophylactic immunoglobulin therapy, antimicrobial therapy, prophylactic therapy, fucose supplementation, monoclonal antibodies, and coagulation factors. Hematopoietic stem cell transplantation involves transplanting stem cells from the bone marrow or blood to replace damaged or diseased blood-forming cells. Treatment and diagnostic services, such as blood tests, genetic testing, biopsies, are provided by various end users, including hospitals and specialty clinics.

The leukocyte adhesion deficiency management market research report is one of a series of new reports from The Business Research Company that provides leukocyte adhesion deficiency management market statistics, including leukocyte adhesion deficiency management industry global market size, regional shares, competitors with a leukocyte adhesion deficiency management market share, detailed leukocyte adhesion deficiency management market segments, market trends and opportunities, and any further data you may need to thrive in the leukocyte adhesion deficiency management industry. This leukocyte adhesion deficiency management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $7.48 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The observed growth in the historic period for the management of leukocyte adhesion deficiency can be attributed to several factors. These include an increase in awareness and education about the disorder, advancements in genetic testing technologies, the designation of orphan drugs for specialized treatment, global health policies supporting rare diseases, the influence of patient advocacy groups, and advancements in pediatric healthcare. These factors collectively contributed to the progress made in addressing leukocyte adhesion deficiency during the historic period.

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the forecast period for the management of leukocyte adhesion deficiency can be attributed to the adoption of precision medicine approaches, the emergence of novel therapeutics, increased accessibility to genetic testing, a shift towards patient-centric drug development, and advancements in immunomodulatory therapies. Major trends expected in the forecast period include innovations in stem cell transplantation techniques, the integration of supportive therapies, the use of telemedicine for remote consultations, collaboration within research networks, and the incorporation of biomarker technologies to enhance diagnostic and treatment strategies.

The rising incidence of primary immunodeficiency (PID) is anticipated to drive the expansion of the leukocyte adhesion deficiency management market. PID encompasses a range of inherited disorders that compromise the immune system's functionality, rendering individuals more vulnerable to infections and diseases due to deficiencies in their immune responses. Managing leukocyte adhesion deficiency can significantly benefit those with primary immunodeficiency, potentially enhancing the understanding of immune system disorders and fostering the development of improved diagnostic techniques and therapies for these conditions. For example, statistics gathered during World Primary Immunodeficiency (WPI) Awareness Week 2023 by the Peace Hospital indicated that an estimated 60 lakh individuals worldwide are affected by PI, with 70% to 90% of cases remaining undiagnosed. Hence, the rising prevalence of primary immunodeficiency is set to propel the growth of the leukocyte adhesion deficiency management market.

The increasing prevalence of spinal cord injuries is expected to drive the growth of the leukocyte adhesion deficiency management market. Spinal cord injury, resulting from damage to any part of the spinal cord or associated nerves, often leads to complications such as autonomic dysfunction, including conditions such as hyperhidrosis. This issue is linked to heightened sympathetic activity in the spinal cord segment located just below the injury site. As indicated by the National Spinal Cord Injury Statistical Center (NSCISC) in March 2022, the estimated annual incidence of traumatic spinal cord injury (SCI) in the United States stands at approximately 54 cases per one million people, equating to about 18,000 new SCI cases annually. Moreover, the estimated count of individuals living with SCI in the United States ranges between 253,000 to 378,000, totaling around 299,000. Hence, the increasing prevalence of spinal cord injuries contributes to the growth of the leukocyte adhesion deficiency management market.

The expansion of the leukocyte adhesion deficiency management market is anticipated to be limited by the high cost of treatment. Leukocyte Adhesion Deficiency (LAD) is a rare condition characterized by issues in leukocyte adhesion and migration due to mutations in the ITGB2 gene. The treatment options for LAD are constrained, and the associated expenses can be substantial. These high treatment costs may restrict access to necessary therapies, hinder the adoption of new treatment approaches, and pose challenges in obtaining specialist consultations. For example, estimates from DVC Stem, a UK-based stem cell treatment clinic, indicate that expenses for a stem cell transplant, a treatment for leukocyte adhesion deficiency, can range widely from $15,000 to $75,000, potentially causing financial strain on patients. Hence, the exorbitant treatment costs are expected to limit the growth potential of the leukocyte adhesion deficiency management market.

Key players in the leukocyte adhesion deficiency management market are strategically concentrating on innovating novel therapies such as RP-L201 to address the fundamental genetic defects and enhance the quality of life for affected individuals. RP-L201, recognized as a Regenerative Medicine Advanced Therapy (RMAT), is designed to facilitate advanced gene therapy for treating leukocyte adhesion deficiency-I (LAD-I). For instance, Rocket Pharmaceuticals, Inc., a US-based clinical-stage company, secured U.S. Food and Drug Administration (FDA) designation for RP-L201 as an RMAT in March 2021. This designation was granted based on promising early-stage safety and efficacy data derived from the ongoing Phase 1/2 clinical trial of RP-L201. The RMAT designation is specifically intended to expedite the development and approval processes for regenerative medicine products, including cell and gene therapies. It is designated to products that demonstrate potential in addressing serious or life-threatening diseases supported by initial clinical evidence of meeting unmet medical needs.

In February 2023, the Jeffrey Modell Foundation (JMF), a non-profit organization dedicated to primary immunodeficiency, entered into a collaboration with Veritas Intercontinental, a healthcare solutions company based in Spain. The collaboration's primary objective is to advance the field of genome and exome sequencing in the context of immunological disorders. By leveraging global expertise and resources, the partnership seeks to identify gene abnormalities associated with primary immunodeficiency conditions, including conditions such as leukocyte adhesion deficiency. This joint effort aims to significantly improve the accuracy of diagnosis and treatment protocols by enhancing the understanding of genetic factors contributing to these immunological disorders.

Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

North America was the largest region in the leukocyte adhesion deficiency management market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the leukocyte adhesion deficiency management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The leukocyte adhesion deficiency management market consists of revenues earned by entities by providing services such as gene therapy, granulocyte transfusions, nutrition, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukocyte adhesion deficiency management market also includes sales of antibiotics such as trimethoprim and sulfamethoxazole. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leukocyte Adhesion Deficiency Management Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leukocyte adhesion deficiency management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leukocyte adhesion deficiency management? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leukocyte adhesion deficiency management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Treatment: Hematopoietic Stem Cell Transplantation; Recombinant Human Interferon-Gamma Treatment; Prophylactic Immunoglobulin Therapy; Antimicrobial Therapy; Prophylactic Therapy; Fucose Supplementation; Monoclonal Antibodies; Coagulation Factors
• 2) By Diagnosis: Blood Test; Genetic Testing; Biopsy; Other Types
• 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; GlaxoSmithKline Plc; Gilead Sciences Inc; Teva Pharmaceuticals Industries Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Leukocyte Adhesion Deficiency Management Market Characteristics

3. Leukocyte Adhesion Deficiency Management Market Trends And Strategies

4. Leukocyte Adhesion Deficiency Management Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Leukocyte Adhesion Deficiency Management Market Size and Growth

• 5.1. Global Leukocyte Adhesion Deficiency Management Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Leukocyte Adhesion Deficiency Management Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Leukocyte Adhesion Deficiency Management Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Leukocyte Adhesion Deficiency Management Market Segmentation

• 6.1. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hematopoietic Stem Cell Transplantation
• Recombinant Human Interferon-Gamma Treatment
• Prophylactic Immunoglobulin Therapy
• Antimicrobial Therapy
• Prophylactic Therapy
• Fucose Supplementation
• Monoclonal Antibodies
• Coagulation Factors
• 6.2. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Blood Test
• Genetic Testing
• Biopsy
• Other Types
• 6.3. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users

7. Leukocyte Adhesion Deficiency Management Market Regional And Country Analysis

• 7.1. Global Leukocyte Adhesion Deficiency Management Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Leukocyte Adhesion Deficiency Management Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Leukocyte Adhesion Deficiency Management Market

• 8.1. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Leukocyte Adhesion Deficiency Management Market

• 9.1. China Leukocyte Adhesion Deficiency Management Market Overview
• 9.2. China Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Leukocyte Adhesion Deficiency Management Market

• 10.1. India Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Leukocyte Adhesion Deficiency Management Market

• 11.1. Japan Leukocyte Adhesion Deficiency Management Market Overview
• 11.2. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Leukocyte Adhesion Deficiency Management Market

• 12.1. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Leukocyte Adhesion Deficiency Management Market

• 13.1. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Leukocyte Adhesion Deficiency Management Market

• 14.1. South Korea Leukocyte Adhesion Deficiency Management Market Overview
• 14.2. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Leukocyte Adhesion Deficiency Management Market

• 15.1. Western Europe Leukocyte Adhesion Deficiency Management Market Overview
• 15.2. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Leukocyte Adhesion Deficiency Management Market

• 16.1. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Leukocyte Adhesion Deficiency Management Market

• 17.1. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Leukocyte Adhesion Deficiency Management Market

• 18.5. France Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Leukocyte Adhesion Deficiency Management Market

• 19.9. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Leukocyte Adhesion Deficiency Management Market

• 20.13. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Leukocyte Adhesion Deficiency Management Market

• 21.1. Eastern Europe Leukocyte Adhesion Deficiency Management Market Overview
• 21.2. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Leukocyte Adhesion Deficiency Management Market

• 22.1. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Leukocyte Adhesion Deficiency Management Market

• 23.1. North America Leukocyte Adhesion Deficiency Management Market Overview
• 23.2. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Leukocyte Adhesion Deficiency Management Market

• 24.1. USA Leukocyte Adhesion Deficiency Management Market Overview
• 24.2. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Leukocyte Adhesion Deficiency Management Market

• 25.1. Canada Leukocyte Adhesion Deficiency Management Market Overview
• 25.2. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Leukocyte Adhesion Deficiency Management Market

• 26.1. South America Leukocyte Adhesion Deficiency Management Market Overview
• 26.2. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Leukocyte Adhesion Deficiency Management Market

• 27.1. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Leukocyte Adhesion Deficiency Management Market

• 28.1. Middle East Leukocyte Adhesion Deficiency Management Market Overview
• 28.2. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Leukocyte Adhesion Deficiency Management Market

• 29.1. Africa Leukocyte Adhesion Deficiency Management Market Overview
• 29.2. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Leukocyte Adhesion Deficiency Management Market Competitive Landscape And Company Profiles

• 30.1. Leukocyte Adhesion Deficiency Management Market Competitive Landscape
• 30.2. Leukocyte Adhesion Deficiency Management Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. GlaxoSmithKline Plc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Gilead Sciences Inc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Teva Pharmaceuticals Industries Limited
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Leukocyte Adhesion Deficiency Management Market Other Major And Innovative Companies

• 31.1. CSL Behring LLC
• 31.2. Vertex Pharmaceuticals Inc.
• 31.3. Grifols International S.A.
• 31.4. Aurobindo Pharma Ltd.
• 31.5. BioMarin Pharmaceutical Inc.
• 31.6. Cadila Healthcare Ltd.
• 31.7. Ipca Laboratories Ltd
• 31.8. Sana Biotechnology Inc.
• 31.9. Rocket Pharmaceuticals Inc.
• 31.10. PT Sanbe Farma
• 31.11. Magenta Therapeutics Inc
• 31.12. Avalo Therapeutics Inc.
• 31.13. Aspen Neuroscience Inc.
• 31.14. Sandoz International GmbH
• 31.15. Orpha Labs Inc.

32. Global Leukocyte Adhesion Deficiency Management Market Competitive Benchmarking

33. Global Leukocyte Adhesion Deficiency Management Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Leukocyte Adhesion Deficiency Management Market

35. Leukocyte Adhesion Deficiency Management Market Future Outlook and Potential Analysis

• 35.1 Leukocyte Adhesion Deficiency Management Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Leukocyte Adhesion Deficiency Management Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Leukocyte Adhesion Deficiency Management Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer